Printer Friendly

ONCOR ANNOUNCES THIRD QUARTER AND NINE MONTHS OPERATING RESULTS; REPORTS NINE MONTHS REVENUES INCREASED 57 PERCENT

    ONCOR ANNOUNCES THIRD QUARTER AND NINE MONTHS OPERATING RESULTS;
          REPORTS NINE MONTHS REVENUES INCREASED 57 PERCENT
    GAITHERSBURG, Md., Nov. 15 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR), a leading manufacturer and marketer of DNA probe-based test systems for the diagnosis, monitoring and management of cancer and other genetic diseases, has reported financial results for its third quarter and nine months ended Sept. 30, 1991, with overall nine-month revenue increasing 57 percent, Stephen Turner, chairman and chief executive officer, announced today.
    Oncor's revenues in the third quarter ended Sept. 30, 1991 were $920,234, which included $200,000 in contract revenues, compared with $696,392 in the third quarter of 1990.  There were no contract revenues in the third quarter of 1990.  The net loss of $1,352,778, or $.13 per share, on 10,016,251 weighted average shares outstanding in the current third quarter compares with a net loss of $982,798, or $.14 per share, on 7,276,000 weighted average shares, which included $185,000 in contract revenue, outstanding in the prior period.
    Gross revenues in the nine months ended Sept. 30, 1991 were $3,643,157, which included $1,050,000 in contract revenues, compared with $2,309,794, which included $185,000 in contract revenues, in the nine months ended Sept. 30, 1990.  The net loss in the current nine months was $2,358,870, or $.26 per share, on 9,023,151 weighted average shares outstanding, compared with a net loss of $1,758,126, or $.24 per share, on 7,276,000 weighted average shares outstanding in the nine months of 1990.
    Turner noted that there was a 135 percent increase in research and development expenses for the nine months when compared with the same period last year, "resulting in a loss for the period, as expected," he said.  "These expenditures, which totaled $1,908,301 this year, are related to expenses associated with the company's contract with Hickley International Ltd. for the development of new DNA and RNA probes, the development of technology underlying new DNA probe tests and the financing of clinical research studies relating to submissions to the FDA under the PMA process (premarket approval) or 510K (premarketing notification processes).  These include tests for breast, bladder and prostate cancers," Turner added.
    Turner said, "Oncor is firmly committed to maintaining a leadership position in the coming era of genetic-based clinical medicine.  We believe that increasing our investments in research and development will be rewarded in the future with a strong, cancer diagnostic product portfolio."
                              ONCOR, INC.
                   Condensed Statement of Operations
                              (Unaudited)
    Periods ended              Three Months            Nine Months
     Sept. 30;              1991        1990        1991        1990
    Gross revenues        $920,234    $696,392   $3,643,157  $2,309,794
    Operating Expense:
     Direct cost of sales  418,388     592,124    1,347,486   1,344,502
     Selling, general
      & administrative     834,870     703,931    2,819,760   1,925,859
     Research &
      development        1,093,387     364,368    1,908,301     810,450
     Total               2,346,645   1,660,423    6,075,547   4,080,811
    Net loss            (1,352,778)   (982,798)  (2,358,870) (1,758,126)
    Net loss per share        (.13)       (.14)        (.26)       (.24)
    Wtd. avg. shares
     outstanding        10,016,251   7,276,000    9,023,151   7,276,000
    -0-            11/15/91
    /CONTACT:  Stephen Turner, chairman & CEO, or Rodney Dausch, vice president-finance, both of Oncor, 301-963-3500/
    (ONCR) CO:  Oncor, Inc. ST:  Maryland IN:  MTC SU:  ERN FC-JT -- NY032 -- 1496 11/15/91 11:28 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1991
Words:580
Previous Article:SUNBELT NURSERY GROUP REPORTS RESULTS FOR THIRD QUARTER ENDED OCT. 31, 1991
Next Article:FLORIDA GAS TRANSMISSION FILES TO CONSTRUCT MAJOR PIPELINE EXPANSION PROJECT
Topics:


Related Articles
TECHNE CORPORATION RELEASES UNAUDITED THIRD QUARTER OPERATING RESULTS FOR FISCAL YEAR 1992
ONCOR REPORTS RECORD NET PRODUCT SALES IN SECOND QUARTER ENDED JUNE 30, 1992
STERLING SOFTWARE ANNOUNCES HIGHER EARNINGS FOR THIRD QUARTER AND FIRST NINE MONTHS
ONCOR, INC. REPORTS RECORD PRODUCT SALES OF $1.5 MILLION IN THE THIRD QUARTER, 1992
COMPANIA DE TELEFONOS DE CHILE S.A. ANNOUNCES RESULTS IN U.S. GAAP FOR THE NINE MONTHS ENDED SEPT. 30, 1992, AND DECLARATION OF DIVIDEND
SPEC'S MUSIC, INC. ANNOUNCES THIRD QUARTER AND NINE MONTHS RESULTS
CONCOURSE CORPORATION REPORTS THIRD QUARTER AND NINE MONTH RESULTS
ONCOR, INC. REPORTS OPERATING RESULTS FOR THIRD QUARTER AND NINE MONTHS OF 1993
ONCOR, INC. REPORTS THIRD QUARTER AND NINE MONTHS RESULTS; THIRD QUARTER REVENUE UP 53% OVER PRIOR YEAR
The Washington Post Company Reports Third Quarter Earnings.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters